Autoantibodies to p53, a common protein dysregulated in cancer, displays an almost 100% specificity, but it has an extremely low sensitivity (range: 4–46%) and may also be detected for other cancers, limiting its utility as a biomarker in CRC [50,54]. This evidence concerns the gene TP53 and cancer.